Dear Colleagues, dear Friends,

It is a great pleasure for us to welcome you at the Swiss Pathology Days, the 83rd Annual Meeting of the Swiss Society of Pathology 2017.

This year, several young staff pathologists and senior residents have had the unique opportunity to participate in the organization of the Swiss Pathology Days supported by the executive board of the Swiss Society of Pathology. As junior medical professionals, we would like to express our thanks to the Society for their assistance and the trust they have put in our team.

In pathology, we currently find ourselves in an exciting era. Advances in technology have opened up many new possibilities, not only in terms of diagnostic tests, but also in the areas of knowledge transfer and communication. The Swiss Pathology Days App is one example of such recent innovation. The App will help you find your way during the conference, download lecture materials and abstracts, and will provide an interactive platform for the main sessions.

We are proud to present this year’s scientific program, which we hope will appeal to both residents in training and experienced pathologists alike. Topics include pattern-based approaches to surgical pathology, an update on new classification systems and immunotherapy. Our competitive abstract submission process will give researchers a podium to present and discuss their projects.

Last but not least, several social events such as the traditional Gala dinner and an informal get-together evening are awaiting you. The impressive backdrop of the Swiss Alps combined with the excellent location and facilities of the KKThun and the Kongresshotel are sure to make for a memorable experience.

We are very much looking forward to welcoming you in Thun and to an exciting and informative meeting!

With best regards on behalf of the organization committee,

Dr. med. Heather Dawson
Congress President

Dr. med. Yasmine Ibrahim
Congress Vice President

Dr. med. Karl-Friedrich Deml
Congress Vice President

---

**ALK-AND ROSI-POSITIVE ADVANCED NSCLC**

**Xalkori® (Crizotinib).**

**Indications:**
- First-line treatment of ALK-positive advanced non-small cell lung cancer (NSCLC);
- Previously treated advanced NSCLC; treatment of ROS1-positive advanced NSCLC.

**Dosage:**
- Adults: 250 mg twice daily with or without food.

**Contraindications:** Hypersensitivity to crizotinib or to any of the excipients.

**Warnings/Precautions for use:**
- Hepatotoxicity,
- ILD/pneumonitis, QT interval prolongation, cardiac failure, vision disorders, gastrointestinal effects, complex renal cyst, renal disorders, lethargy, pancreatitis, epistaxis, rhabdomyolysis, rash, dysgeusia, vision disorders, cardiac failure, bradycardia, QT prolonged, syncope, ILD/pneumonitis, nausea, dizziness, vomiting, constipation, weight gain, dermatologic disorders, dysgeusia, elevated transaminases, dyspepsia, edema, fatigue, etc.

**Interactions:**
- CYP3A4 substrates (e.g., midazolam, alfentanil, cyclosporine, loperamide), CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, azithromycin, cimetidine, ranitidine, atazanavir, saquinavir), grapefruit juice, CYP3A4 inducers (e.g., phenytoin, rifabutin, rifampin), CYP2B6 substrates (e.g., bupropion, efavirenz, (S)-ketamine).

**Undesirable effects:**
- Neutropenia, leukopenia, lymphopenia, thrombocytopenia, blood testosterone decreased, decreased appetite, diarrhoea, dyspepsia, nausea, vomiting, constipation, weight gain, dermatologic disorders, dysgeusia, elevated transaminases, dyspepsia, edema, fatigue, etc.
Table of content

Invitation 2017 3
Organization 5
General Information 6-7
Program at a glance 9
Scientific program 10-17
Speakers and chairs 19
Poster presentations 20-25
Exhibition 27
Sponsored lecture 29
Kind thanks to all our sponsors 30-31
Save the dates 2018 & 2019 32

Organization

Congress President Heather Dawson, Bern
Congress Vice Presidents Karl-Friedrich Deml, Münsterlingen Yasmine Ibrahim, Geneva
Organizing Committee Annika Blank, Bern Patricia Caseiro Silverio, Geneva Jürgen Hench, Basel Viktor Kölzer, Bern Matthias Matter, Basel Tatjana Vlajnic, Basel
Scientific Committee Laurence De Leval, Lausanne Rainer Grobholz, Aarau Wolfram Jochum, St. Gallen Luca Mazzucchelli, Locarno Tilman Rau, Bern Luigi Terracciano, Basel
SGPath/SSPath President Gieri Cathomas, Liestal Vice President Alessandro Lugli, Bern Secretary Zsuzsanna Varga, Zürich Past President Laura Rubbia-Brandt, Geneva
General information

Congress venue
Kultur- und Kongresszentrum KKThun
Seestrasse 68, CH-3602 Thun
www.kkthun.ch

Registration & Congress secretariat
Meeting com Congress Organisation
Rue des Pâquis 1 • CP 100
CH-1033 Cheseaux-sur-Lausanne
T 021 312 92 61 • F 021 312 92 63
nicole.giacomini@meeting-com.ch

Online registration on www.meeting-com.ch
Onsite registration also possible (onsite fee)

Registration fees

<table>
<thead>
<tr>
<th>Category</th>
<th>Early fee (before Sept 30, 2017)</th>
<th>Late fee &amp; onsite (as of Oct 1, 2017)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Residents/students/technicians</td>
<td>150.00</td>
<td>200.00</td>
</tr>
<tr>
<td>SSPath members</td>
<td>250.00</td>
<td>280.00</td>
</tr>
<tr>
<td>SSPath non-members</td>
<td>290.00</td>
<td>320.00</td>
</tr>
<tr>
<td>CONGRESS DINNERS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FRIDAY, 10.11.2017</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gala Dinner KKThun</td>
<td>80.00</td>
<td>free</td>
</tr>
</tbody>
</table>

Payment/confirmation
After your registration/payment, you will receive our invoice/confirmation by email to the address given when registering. Payment by credit card upon registration online is possible, as well as onsite (onsite fee).

Included in registration fee

Not included in the registration fee
The Gala Dinner is not included and has to be booked separately when registering (CHF 80.00). Places are limited and a reservation is required.

Certificate of attendance
The certificate of attendance will be sent by email to all participants after the event.

Cancellation
Written notification is required for all cancellations and changes. In case of cancellation 30 days prior the event, the refund of the amount paid will be done net of CHF 60.00 for administrative costs. Thereafter no refund is possible. Any registration made within the “early bird” time must be paid during this period. If not the case, the invoice is automatically updated at the current price. Administrative costs will be charged to no shows. Legal jurisdiction is Lausanne.

Oral presentations
There are three oral presentation sessions: two on Friday 10.11.17 (11.15 and 16.30) and one on Saturday 11.11.17 at 16.30.

Poster sessions
There are two moderated poster sessions: one during lunch of Friday 10.11.17 at 12.00 and one during lunch of Saturday 11.11.17 at 12.00.

Language
The language of the congress is English.

Industrial exhibition
An industrial exhibition will take place at the Congress venue on Friday 10.11.17 and Saturday 11.11.17.

Hotel booking

Credits

<table>
<thead>
<tr>
<th>Day</th>
<th>Credits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday 10.11.17</td>
<td>8 credits</td>
</tr>
<tr>
<td>Saturday 11.11.17</td>
<td>8 credits</td>
</tr>
<tr>
<td>Sunday 12.11.17</td>
<td>3 credits</td>
</tr>
</tbody>
</table>

Per slide seminar
1 credit (attending) + 1 credit (rendering diagnoses)

Internet access
An internet access will be available throughout the event. Information at the welcome desk.

APP
A SGPATH2017 App is available here: www.dotplus.ch/Event-Code: spd17 or in scanning this QR code
## Program at a glance

<table>
<thead>
<tr>
<th>Time</th>
<th>Friday, November 10</th>
<th>Saturday, November 11</th>
<th>Sunday, Nov. 12</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00-08.30</td>
<td>Registration Foyer</td>
<td>Registration Foyer</td>
<td>From 08.30</td>
</tr>
<tr>
<td>09.00-10.15</td>
<td>MAIN SESSION 1 Schadausaal</td>
<td>MAIN SESSION 3 Schadausaal</td>
<td>From 08.30</td>
</tr>
<tr>
<td>10.15-10.45</td>
<td>Coffee break Exhibition &amp; Poster area</td>
<td>Coffee break Exhibition &amp; Poster area</td>
<td>09.30-10.45</td>
</tr>
<tr>
<td>10.45-11.15</td>
<td>MAIN SESSION 1 Schadausaal</td>
<td>slider Seminar 1 Schadausaal</td>
<td>GENERAL ASSEMBLY</td>
</tr>
<tr>
<td>11.15-12.00</td>
<td>ORAL PRESENTATIONS 1 Schadausaal</td>
<td>Director's conference Workshop 1</td>
<td>Schadausaal</td>
</tr>
<tr>
<td>12.00-13.30</td>
<td>POSTER SESSION 1 Poster area</td>
<td>POSTER SESSION 2 Poster area</td>
<td>10.45-11.15</td>
</tr>
<tr>
<td>13.30-15.00</td>
<td>MAIN SESSION 2 Schadausaal</td>
<td>Lunch Exhibition &amp; Poster area</td>
<td>SLIDE SEMINAR 2</td>
</tr>
<tr>
<td>15.00-16.00</td>
<td>Coffee break Exhibition &amp; Poster area</td>
<td>Lunch Exhibition &amp; Poster area</td>
<td>Schadausaal</td>
</tr>
<tr>
<td>16.00-16.30</td>
<td>MAIN SESSION 2 Schadausaal</td>
<td>15.00-15.30 Coffee break</td>
<td>11.15-12.15</td>
</tr>
<tr>
<td>16.30-17.00</td>
<td>ORAL PRESENTATIONS 2 Schadausaal</td>
<td>16.30-17.00 ORAL PRESENTATIONS 3 Schadausaal</td>
<td>11.15-12.15</td>
</tr>
<tr>
<td>18.30</td>
<td>Aperitif &amp; Gala Dinner Foyer Lachen</td>
<td>18.30 Get-Together Congress Hotel Seepark</td>
<td>12.30 End of congress</td>
</tr>
</tbody>
</table>

### Maxwell RSC For Liquid Biopsy

The Maxwell’ Rapid Sample Concentrator (RSC) Instrument with the integrated Quantus™ Fluorometer allows isolation of ccfDNA from up to 16 plasma samples in a single run.

- Obtain high yields of amplifiable ccfDNA
- Simply add 1ml of plasma to the cartridges and start the automated run
- Purify ccfDNA from 2-4ml of plasma with a modified protocol and simple preprocessing

For more information visit: [www.promega.com/MaxwellRSC](http://www.promega.com/MaxwellRSC)
Friday, November 10, 2017

From 8.00
Registration

09.00-09.15
Opening ceremony
Schadausaal

09.15-11.15
MAIN SESSION 1
Schadausaal
Chairs: Karl-Friedrich Deml, Münsterlingen; Tatjana Vlajnic, Basel

09.15-09.45
A practical approach to breast biopsies
Zsuzsanna Varga, Zürich

09.45-10.15
A practical approach to prostate biopsies
Achim Fleischmann, Münsterlingen

10.15-10.45
Coffee break – Visit of the exhibition – Poster viewing
Exhibition & Poster area

10.45-11.15
A practical approach to lung biopsies
Hans-Ulrich Schildhaus, Göttingen (D)

11.15-12.00
ORAL PRESENTATIONS – SESSION 1: 01 - 04
Schadausaal

01
PD-L1 testing using concentrated 22C3 antibody: results of the Swiss cross-validation study

02
Tumor purity enrichment applying a unique flow-sorting approach to study intratumoral heterogeneity in matched samples of squamous cell carcinoma of the lung
Arthur Krause1, Thomas Lorber1, Tanja Dietsche1, Michael Barrett2, Christian Ruiz1, Lukas Bubendorf1
1Institute of Pathology, University Hospital Basel, 2Mayo Clinic, Arizona, Scottsdale (US)

03
Implications of routine NGS testing for daily clinical practice – the Zurich experience with the OFA panel
Nadejda Valtcheva1, Christian Diehl1, Markus Rechsteiner1, Sandra N. Freiberger1, Christine E. Wong1, Annette Bohnert1, Elisa Bellini1, Qing Zhong1, Ulrich Wagner1, Alessandra Curioni1, Alexander Siebenhüner1, Christian Britschgi1, Peter J. Wild1
1University Hospital Zurich

04
Genetic profiling of cell-free plasma DNA from patients with therapy-naïve hepatocellular carcinoma
Charlotte Ng1, Nadia Tosti1, Viola Paradiso1, Valeria Perrina1, Cristina Quintavalle1, Manuela Lanzafame1, Luca Quagliata1, Matthias Matter1, LuigiTerracciano1, Salvatore Piscuoglio1
1University Hospital Basel

11.00-12.00
Director’s conference
Workshop 1

12.00-13.30
Lunch – Visit of the exhibition & poster session
Exhibition area

12.00-13.30
POSTER SESSION 1: P1 - P16
Poster area

Moderated by Holger Moch, Zürich; Sabina Berezowska, Bern
Friday, November 10, 2017

13.30-16.30
MAIN SESSION 2
Schadausaal

Chairs: Yasmine Ibrahim, Geneva; Matthias Matter, Basel

13.30-14.00
Molecular pathology of lung cancer
Reinhard Büttner, Cologne (D)

14.00-14.30
Methylation profiling of brain cancers
David Capper, Berlin (D)

14.30-15.00
The new WHO/TNM classification and new entities in the field of gastroenteropancreatic neuroendocrine neoplasms
Stefano La Rosa, Lausanne

15.00-16.00
Coffee break – Visit of the exhibition – Poster viewing
Exhibition & Poster area

16.00-16.30
Molecular pathology of head and neck tumors
Niels Rupp, Zürich

16.30-17.00
ORAL PRESENTATIONS – SESSION 2: 05 - 07
Schadausaal

05
High-throughput sequencing of nodal marginal zone lymphomas identifies BRAF V600E hotspot mutations
Vincent Pillonel¹, Darius Juskevicius¹, Charlotte Ng¹, David Jucker¹, Stefan Dirnhofer¹, Alexandar Tzankov¹
University Hospital Basel

06
Visualization of hepatitis E virus RNA and proteins in the human liver
Daniela Lenggenhager¹, Jérôme Gouttenoire², Mohsen Malehmir¹, Marion Bawohl¹, Hanna Honcharova-Biletska¹, Susanne Kreutzer¹, David Semela³, Jörg Neuweiler³, Sandra Hürlimann⁴, Patrick Aepli⁴, Montserrat Fraga⁵, Roland Sahli², Luigi Terracciano⁶, Laura Rubbia-Brandt⁶, Beat Müllhaupt⁷, Christine Sempoux⁸, Darius Moradpour², Achim Weber¹
¹University Zurich and University Hospital Zurich, ²Centre Hospitalier Universitaire Vaudois, University of Lausanne, ³Cantonal Hospital St. Gallen, ⁴Cantonal Hospital Lucerne, ⁵University Hospital Basel, ⁶Geneva University Hospitals Faculté de Médecine Geneva, ⁷University and University Hospital Zurich

07
Patient-derived renal cancer cell models as a tool for research and precision medicine
Hella Bolck¹, Claudia Corro¹, Chantal Pauli¹, Adriana Von Teichman¹, Raquel Herrador¹, Katharina Mühlbauer¹, Susanne Dettwiler¹, Fabiola Prutek¹, Peter Schraml¹, Holger Moch¹
¹University Hospital Zurich

18.30
Welcome drink, Gala Dinner & Award Ceremony
Foyer Lachen
Saturday, November 11, 2017

**From 8.00**
Registration

**09.00-10.30 MAIN SESSION 3**
*Chair: Jürgen Hench, Basel; Viktor Koelzer, Oxford (UK)*

- 09.00-09.30 *Introduction to the effects and side effects of immunotherapy*
  Krisztian Homicsko, Lausanne

- 09.30-10.00 *The role of surgical pathology in guiding cancer immunotherapy*
  Scott Rodig, Boston (US)

- 10.00-10.30 *Development of an immunotherapy response index for oncology: an integrated NGS model*
  Mark Rubin, Bern

**10.30-11.00**
Coffee break – Visit of the exhibition – Poster viewing

**11.00-12.00 SLIDE SEMINAR 1**
*Common immunotherapy-associated tissue pathology*
*Chairs: Jürgen Hench, Basel; Viktor Koelzer, Oxford (UK)*
Scott Rodig, Boston (USA)
Werner Kempf, Zurich
Jürgen Hench, Basel

**12.00-13.00**
Lunch – Visit of the exhibition & poster session

**13.30-16.30 MAIN SESSION 4**
*Chair: Annika Blank, Bern; Heather Dawson, Bern*

- 13.30-14.00 *A pattern-based approach to the non-neoplastic liver biopsy*
  Laura Rubbia-Brandt, Geneva

- 14.00-14.30 *A pattern-based approach to the neoplastic liver biopsy*
  Luigi Terracciano, Basel

- 14.30-15.00 *Inflammatory bowel disease-related neoplasia: an update*
  Magali Svrcek, Paris (F)

- 15.30-16.00 *Pearls and pitfalls in handling endoscopic mucosal resections*
  Benoît Terris, Paris (F)

- 16.00-16.30 *Effects on NSAIDs in the gastrointestinal tract*
  Michael Vieth, Bayreuth (D)
Saturday, November 11, 2017

16.30-17.00 ORAL PRESENTATIONS – SESSION 3: 08 - 010 Schadausaal

08 Genomic analysis revealed new oncogenic signatures in TP53-mutant hepatocellular carcinoma
Venkatesh Kancherla¹, Samir Abdullazade¹, Matthias Matter¹, Luca Quagliata¹, Luigi Terracciano¹, Charlotte Ng¹, Salvatore Piscuoglio¹
¹University Hospital Basel

09 Three cases of SDHC epimutated gastrointestinal stromal tumours: clinical and pathological features
Ruth Casey¹, Johanne E. Anstee¹, Rogier Ten Hoopen¹, Eamonn Maher¹, Olivier Giger¹
¹Cambridge University, Cambridge (GB)

010 CDX2 loss in colorectal cancer is an independent adverse prognostic factor and can be restored by de-methylation and inhibition of histone deacetylation
Kristin Uth¹, Janina Graule¹, Alessandro Lugli¹, Mario Tschan¹, Inti Zlobec¹
¹University of Bern

18.30 Get-Together Congress Hotel Seepark
At the Congress Hotel Seepark
Seestrasse 47, 3602 Thun

Sunday, November 12, 2017

From 08.30 Registration Schadausaal

09.30-10.45 GENERAL ASSEMBLY Schadausaal

10.45-11.15 Coffee break Foyer Schadausaal

11.15-12.15 SLIDE SEMINAR 2 Schadausaal
Dermatopathology
Chairs: Patricia Caseiro Silverio, Geneva; Yasmine Ibrahim, Geneva
Helmut Beltraminelli, Bern
Werner Kempf, Zurich
Gürkan Kaya, Geneva

12.30 End of the Swiss Pathology Days 2017
Discover a new world

With the unique and revolutionary H&E solution from Roche.

The VENTANA HE 600 system enables you to improve

• The efficiency of your lab
• The quality and consistency of your stain
• The technician safety
• The patient safety

VENTANA
Empowering | Innovation

© 2017 Roche
VENTANA is a trademark of Roche.
Roche Diagnostics (Switzerland) Ltd · 6343 Rotkreuz · E-Mail info.rdch@roche.com · Phone +41 41 799 61 00
www.roche-diagnostics.ch
Poster presentations

P1
Therapies that control serum insulin enhance the effectiveness of PI3K-inhibitors as anti-cancer agents
Chantal Pauli1, Benjamin David Hopkins2, Mark A Rubin1, Siddhartha Mukherjee4, Lewis C. Cantley2
1 University Hospital Zurich, 2 Weill Cornell Medicine, New York (US), 3 University of Bern, 4 Columbia University Medical Center and New York Presbyterian Hospital, New York (US)

P2
Integration of the Oncomine cfDNA Assay in Routine Clinical Practice - the Zurich Experience
Markus Rechsteiner1, Nadejda Valtcheva1, Sandra N. Freiberger1, Christine E. Wong1, Peter J. Wild1
1 University Hospital Zurich

P3
Exploring the role of astrocytes in neuroinflammation
Kristof Egervari1, Karin Steinbach2, Nicolas Page2, Ilena Vincenti2, Giovanni Di Liberto2, Bogna Klimke2, Mario Kreutzfeldt2, Karim Hammad2, Ingrid Wagner2, Doron Merkler1
1 Geneva University Hospitals; University of Geneva, 2 University of Geneva

P4
Angiotropic tumor spread in melanoma brain metastases: eight documented autopsy cases.
Ann-Katrin Rodewald1, Elisabeth J. Rushing2, Daniel Kirschenbaum2, Joanna Mangana3, Christiane Mittmann3, Holger Moch3, Claire Lugassy3, Raymond L. Barnhill1, Daniela Mihic-Probst2
1 Triemli Hospital Zurich, 2 University Hospital Zurich, 3 Institut Curie, Paris (FR)

P5
Squamous cell carcinoma of the lacrimal sac: Case report and review of literature with regard to the anatomy and histology of the lacrimal drainage system
Umberto Maccio1, Marco Bühler1, Mirjana Manestar2, Holger Moch1, Daniel Zweifel1, Daniela Mihic-Probst1
1 University Hospital Zurich, 2 University of Zurich

P6
Papillary thyroid carcinoma – new epigenetic insights: miRNA’s predicting prognosis
Matthias Dettmer1, Anja Schmitt1, Holger Moch2, Paul Komminoth3, Yuri Nikiforov4, Marina Nikiforova4, Aurel Perren1
1 University of Bern, 2 University Hospital Zurich, 3 Triemlispital, Zurich, 4 University of Pittsburgh Medical Center, Pittsburgh (US)

P7
Antidepressants-related black thyroid: clinico-pathologic description of a case.
Jean-Luc Barras1, Rossella Sarro1, Massimo Bongiovanni1, Stefano La Rosa1
1 Lausanne University Hospital

P8
Mucoepidermoid carcinoma of the palate presenting as an intraoral squamous papilloma. Description of a challenging case.
Rossella Sarro1, Sonia Ziaidi1, Celine Gu1, Massimo Bongiovanni1, Bettina Bisig1, Stefano La Rosa1
1 Lausanne University Hospital

P9
ROR1 expression in lung adenocarcinoma: a putative marker for new molecular targeted therapies
Samantha Epistolio1, Vittoria Martin1, Francesca Molinari1, Luciano Wannesson2, Giovanna Schiavone1, Jessica Barizzi1, Luca Mazzucchelli1, Milo Frattini1
1 Istituto cantonale di patologia, Locarno, 2 IISI, Bellinzona, 3 EOC, Mendrisio

P10
Coexisting pulmonary adenocarcinoma and Langerhans cell histiocytosis/hyperplasia: a rare association in a non-smoking woman
Marie Maillard1, Sandrine Vijgen2, Catherine Beigelman2, Igor Letovanec1
1 Institute of Pathology, University Hospital Lausanne, 2 Institute of Pathology, University Hospital Lausanne, 3 Department of radiology, University Hospital Lausanne
P11
Automated classification of Non-Small Cell Lung Cancer histologic subtypes by deep learning
Ruben Casanova1, Elvis Murina2, Oliver Dürr2, Beate Sick2, Alex Soltermann1
1University Hospital Zurich, 2Zurich University of Applied Sciences / ZHAW, Winterthur

P12
p53 expression in patients with renal cell carcinoma correlates with a higher probability of disease progression and increased cancer-specific mortality after surgery but does not enhance the predictive accuracy of robust outcome models
Laura Morshäuser1, Matthias May2, Maximilian Burger3, Wolfgang Otto5, Georg Hutterer7, Tobias Klatte6, Martin Pichler4, Peter J. Wild4, Lorenz Buser5, Sabine Brookman-may1
1Ludwig-Maximilians University LMU, Munich (DE), 2St. Elisabeth Hospital Straubing, Straubing (DE), 3University Regensburg, Regensburg (DE), 4Medical University Graz, Graz (AT), 5Medical University Vienna (AT), 6University Hospital Zurich

P13
Breast implant-associated anaplastic large-cell lymphoma presenting as a tumor mass and recurring as a seroma, with dual JAK1 and STAT3 mutations
Bettina Bisig1, Audrey Letourneau1, Marie Maerevoet2, Dina Milowich1, Roland Dewind2, Edoardo Missiaglia1, Laurence de Leval1
1Lausanne University Hospital, 2Institut Jules Bordet, Brussels (BE)

P14
RNA fusions involving CD28 contribute to mutations-induced TCR signaling activation in peripheral T-cell lymphomas of TFH derivation
David Vallois1, Aurélie Dupuy2, Francois Lemonnier2, Virginie Fataccioli2, Nicolas Ortonne2, George Allen1, Olivier Tournilhac3, Richard Delarue4, Marie-christine Rousselet5, Bettina Fabiani6, Francisco Llamas Gutierrez7, Young Hyeh Ko8, Keisuke Kataoka9, Philippe Gaulard2, Laurence de Leval1
1Centre Hospitalier Universitaire Vaudois, University of Lausanne, 2Hôpital Henri-Mondor/INSERM U955/Université Paris-Est, Créteil (FR), 3CHU Estang, Clermont-Ferrand (FR), 4Hôpital Necker enfants malades, Paris (FR), 5CHU Angers, Angers (FR), 6Hôpital Saint-Antoine, Paris (FR), 7CHU Rennes, Rennes (FR), 8Samsung medical center/Sungkyunwan University School of medicine/ Ewha Womans University, Seoul (KR), 9Graduate school of medicine/Kyoto University, Kyoto (JP)

P15
Clonogenic versus morphogenic mutations in myeloid neoplasms
Magdalena Gerlach1, Pontus Lundberg1, Joerg Halter1, Christian Arranto1, Friedel Wenzel1, Stefan Dirnhofer1, Alexandar Tzankov1
1University Hospital Basel

P16
Germline RET Mutations and Susceptibility to Osteosarcoma
Michal Kovac1, Sebastian Ribi2, Claudia Blattmann3, Eva Roth4, Wolfgang Hartmann5, Mandy Ballinger6, David Thomas4, Michaela Nathrath7, Karl Heinimann8, Daniel Baumhoer1
1Institute of Pathology, University Hospital Basel, 2Institut für Pathologie, Basel, 3Klinikum Stuttgart Olbgahospital, Stuttgart (DE), 4University of Heidelberg, Heidelberg (DE), 5University Hospital Münster, Münster (DE), 6Garvan Institute of Medical Research, Darlinghurst (AU), 7Klinikum Kassel, Kassel (DE), 8University Hospital Basel

P17
Assessment of predictive biomarkers in cancer tissues using micro-immunohistochemistry followed by DNA sequencing
Anne-Laure Leblond1, Ruben Casanova1, Markus Rechsteiner1, Peter J. Wild1, Amy Jones3, Deborah Heintze2, Ata Tuna Ciftlik4, Alex Soltermann1
1University Hospital Zurich, 2EPFL, Lausanne

P18
New, more sensitive assays for EGFR characterization in liquid biopsies
Samantha Epistolio1, Majbritt Hauge Kyneb2, Michael Borgesen2, Rasmus Koefoed Petersen1, Giulia Ramelli1, Francesca Molinari1, Christina Andersen3, Luca Mazzucchelli1, Jan Lorenzen2, Ulf Bech Christensen3, Milo Frattini1
1Istituto cantonale di patologia, Locarno, 2Danish teknologisk institut, Aarhus C (DK), 3PentaBase Aps, Odense C (DK)

P19
Fast Track Mutation Analysis to enable urgent treatment decisions using the Idylla™ System
Sandra N. Freiberger1, Markus Rechsteiner1, Nadejda Valtcheva1, Peter J. Wild1
1University Hospital Zurich
Quality assurance of surgical pathology diagnoses by retrospective review. The Locarno experience.
Eliana Passega Sidler¹, Luca Mazzucchelli¹
¹Institute of Pathology, Locarno

Clinical autopsies in Switzerland. A status report
Ann-Katrin Rodewald¹, Peter Bode¹, Gieri Cathomas², Holger Moch¹
¹University Hospital Zurich, ²Institut für Pathologie, Kantonsspital Baselland, Liestal

A role of JNK signaling for biliary tract formation
Hanna Honcharova-Biletska¹, Michele Egger-Sigg¹, Friederike Böhm¹, Yannick Boege¹, Marc Healy¹, Johannes Schmitt¹, Roger Davis², Mathias Heikenwalder³, Achim Weber¹
¹University Hospital Zurich, ²University of Massachusetts Medical School, Worcester, (US), ³Deutsches Krebs-Forschungszentrum (DKFZ), Heidelberg (DE)

Correlation of histologic features and genomic landscape in hepatocellular carcinoma
Venkatesh Kancherla¹, Samir Abdullazade¹, Matthias Matter¹, Salvatore Piscuoglio¹, Charlotte Ng¹, Luigi Terracciano¹
¹University Hospital Basel

Fine-mapping of chromosomal aberrations in NASH-HCC by single-cell FISH
Juliane Friemel¹, Elizabeth Brauneis², Irianna Torres², Thomas Ried², Achim Weber³, Kerstin Heselmeyer-Haddad²
¹University and University Hospital Zurich, ²National Cancer Institute, Bethesda (US), ³University Hospital Zurich

TEAD4 Expression in Human Hepatocellular Carcinoma Correlates with Poor Prognosis and Promotes Tumor Growth and Migration
Nadia Tosti¹, Manuela Lanzafame¹, Viola Paradiso¹, Cristina Quintavalle¹, Charlotte Ng¹, Luigi Terracciano¹, Salvatore Piscuoglio¹
¹University Hospital Basel
Your partner for clinical pathology. We offer the most advanced technologies in:

> Histology  
> Molecular Pathology  
> Genetics  
> Cytology

One provider for all of your needs.

www.synlab.ch
SMART Automation is the logical next step to enhance laboratory performance. Maximize your laboratory’s productivity, while reporting better turnaround times and consistent quality, using the same resources.

Millions of patients around the world have benefited from better and faster diagnoses offered by the histopathology laboratories that have implemented SMART Automation.

SMART Automation labs reported:

- Increased productivity by more than 30%, with the same number of technicians
- Reduced time to diagnose by 67%
- 80% of the cases are ready within 24 hours
- Better control of the daily process

Sakura Finetek Europe B.V.
www.smartautomation.com
smartautomation@sakura.com

Distributed in Switzerland by:
Sysmex Suisse AG
8810 Horgen

SMART Automation, maximizing productivity

Il s'agit d'un soutien d'une session de 30 minutes sur la base du programme scientifique, le sponsor n'a pas d'influence ni sur le contenu ni sur le choix de l'orateur (responsabilité de la SGPath).

Es handelt sich um eine finanzielle Unterstützung für einen 30-minütigen Vortrag auf der Grundlage des wissenschaftlichen Programms. Der Sponsor hat keinerlei Einfluss auf den Inhalt oder auf die Wahl des Referenten, dieses obliegt alleine der SGPath.
Kind thanks to all our sponsors
Save the dates

2018
SWISS PATHOLOGY DAYS

Thursday 8 – Friday 9 – Saturday 10 November 2018
Palazzo dei Congressi, LUGANO
Piazza Indipendenza 4, CH-6900 Lugano
www.luganoconventions.com

2019
4th JOINT ANNUAL MEETING
of the Swiss and Austrian Societies of Pathology

Thursday 7 – Friday 8 – Saturday 9 November 2019
Kultur- und Kongresszentrum, KKL LUCERNE
Europaplatz 1, CH-6005 Lucerne
www.kkl-luzern.ch